EVADE Study Update June 2018

As of today, 543 subjects have been enrolled in the EVADE study, of which 94 have been randomized. While only 2 randomizations occurred during the month of May despite screening 31 subjects, the first half of June has been very successful with 5 randomizations.

Randomized patients

There are currently 74 active sites in the following countries: Austria, Belgium, Croatia, Czech Republic, France, Greece, Hungary, Ireland, Israel, Portugal, Spain and Turkey, UK, and US. 61 of these 74 sites have actively screened at least 1 patient and 34 have randomized at least 1 patient. Congratulations go to the sites of Dr Ferrer Roca (Hospital Universitario Vall d’Hebron, Barcelona, Spain), Dr Klouche (Centre Hospitalier Universitaire de Montpellier/ Lapeyronie hospital, Montpellier, France) and Dr Korten (Marmara University Research and Training Hospital, Istanbul, Turkey) who have randomized their first patient.

About EVADE

EVADE is a Phase II, randomized, controlled safety and efficacy trial of MEDI3902. It is a bispecific monoclonal antibody against two Pseudomonas aeruginosa proteins, for the prevention of ventilator-associated pneumonia in adult ICU-patients. In collaboration with MedImmune/AstraZeneca, up to 120 ICUs will participate in this study.